newsfilter
← Latest News
ACCESS Newswire·

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

- DMT310 Phase 3 Spongilla Treatment of Acne Research clinical trial enrollment remains on track -- Dermata continues discussions with potential botulinum toxin partners for DMT410 -- Received issuance of